Unlock instant, AI-driven research and patent intelligence for your innovation.
Cinepazide medicinal composition with high safety, preparation method and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of cinepazide and composition, which is applied in the field of cinepazide pharmaceutical composition and its preparation, and can solve problems such as not effectively reducing
Active Publication Date: 2010-05-19
BEIJING SIHUAN PHARMA
View PDF0 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0009] However, the above-mentioned quality control measures have not effectively reduced or avoided the decline in blood images of patients caused by cinepazide.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0066] Example 1 Preparation of cinepazide nitrogen oxide
[0067] Dissolve 2 grams of cinepazide in 100 ml of dichloromethane, add 10 grams of peracetic acid, stir until the reaction is complete, filter, spin the filtrate, recrystallize with ethanol, and then freeze-dry to obtain 0.52 g of cinepazide special nitrogen oxides. HPLC peak area normalization method, the measured content is not less than 98%.
[0069] Example 2 Preparation of cinepazide nitrogen oxide
[0070]Dissolve 2 grams of cinepazide in 100ml of methanol, add 5 grams of peroxybenzoic acid, stir until the reaction is complete, filter, spin the filtrate, and use preparative high-efficiency liquid phase separation, mobile phase is methanol-water, gradient wash Take off and receive the product fraction to obtain 0.3 g of cinepazide nitrogen oxide. HPLC peak area normalization method, the measured content is not less than 99%.
[0072] Example 3 Preparation of cinepazide nitrogen oxide
[0073] Dissolve 5 g of cinepazide maleate in 25 ml of water, add 25 ml of 25% hydrogenperoxide, stir and react at room temperature for 5 days, use preparative high-efficiency liquid phase separation, mobile phase is acetonitrile-water, gradient elution, receive The fraction of the product obtained 500 mg of cinepazide nitrogen oxide. HPLC peak area normalization method, the measured content is not less than 99%.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to a medicine composition with high safety, a preparation method and an application thereof. The medicine composition contains cinepazide or salt thereof which is acceptable in pharmacy and a structural compound which has the content not higher than 0.5% and is shown in the formula (III). The cinepazidemedicine composition and a preparation thereof have better safety, effectiveness and stability and can effectively lower or avoid the adverse reactions of hemogram lowering and the like of a patient caused by the cinepazide. Furthermore, the invention also separates, purifies and characterizes a novel cinepazide nitrogenoxide, researches the novel cinepazide nitrogenoxide fully and discovers that the toxicity of the compound is far greater than that of the cinepazide and the compound has an insecticidal activity which is different from that of the cinepazide. Meanwhile, the research discovers that the cinepazide nitrogenoxide can cause the leukopenia of animals, even influences the formation and the differentiation of granular cells and is possibly a main reason of the adverse reactions of the hemogram lowering and the like of the patient caused by the cinepazide.
Description
technical field [0001] The invention belongs to cardiovascular and cerebrovascular expansion drugs, and in particular relates to a high-safety cinepazide medicinal composition, a preparation method thereof and an application thereof. Background technique [0002] Cardiovascular and cerebrovascular diseases, like cancer, have become common and frequently-occurring diseases that seriously threaten people's health. Therefore, the preparation and selection of safer and more effective cardiovascular and cerebrovascular drugs has become an important research topic in the field of medicine. [0003] Cinepazide is a cardiovascular and cerebrovascular dilating drug. It has been widely used in countries all over the world because of its definite curative effect. Its chemical name is (E)-1-{4-[(3′,4′,5′- Trimethoxycinnamoyl)]-1-piperazine}acetylpyrrolidine, having the following structure: [0004] Formula (I). [0005] Cinepazide is mainly used in the prevention and treatment of t...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
